Endometrium Cancer Clinical Trial
— ENCA-1Official title:
Positron Emission Tomography and Computed Tomography in the Management of Early Stage Intermediate and High-risk Endometrial Cancer
NCT number | NCT03570866 |
Other study ID # | ENCA-1 |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2022 |
Est. completion date | May 1, 2024 |
Endometrial cancer (EC) is the most common gynecologic malignancy in the developed countries and is the fifth most common cancer among women worldwide. Typically present well or moderately differentiated, early stage endometrioid histotype with a prognosis usually favorable. Pelvic lymph nodes (LNs) represent the most common site of extra-uterine disease in patients with clinical early stage disease and the role of lymphadenectomy in early stage EC has been one of the major controversies in gynecology oncology. Lymphadenectomy doesn't improve survival or reduce disease recurrence although supported to provide prognostic information and allowing tailoring of adjuvant therapy. Nevertheless, lymphadenectomy is not performed without serious short-term and long-term morbidity. Although surgical staging is the most accurate and standard method to determine LNs involvement, the introduction in clinical practice of a non-invasive modality that allows an accurate staging of EC would be essential. Available evidence report the accuracy of Positron Emission Tomography and Computed Tomography (PET/CT) for the detection of LN metastasis in EC with a sensitivity of 63% and specificity of 94.7%. This prospective comparative analysis between PET/CT, histological findings, and follow up data will be performed to investigate the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of integrated PET/CT for nodal staging of EC per patient and per LN chain analyses, in women affected by intermediate (grade 1 and 2 endometrioid lesions with deep myometrial invasion > 50% or grade 3 endometrioid lesion with < 50% myometrial invasion) or high risk (grade 3 endometrioid lesion with deep myometrial invasion > 50% or non-endometrioid histotype) early-stage EC. Furthermore, the preoperative classification of EC in intermediate and high-risk class will allow to investigate its prognostic value.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | May 1, 2024 |
Est. primary completion date | May 1, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Women with diagnosis of early stage intermediate and high-risk endometrial cancer. Exclusion Criteria: - Not eligible for standard surgical treatment; Not eligible for preoperative staging with PET/CT |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Università degli Studi dell'Insubria | Universita di Verona |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic accuracy of positron emission tomography and computed tomography | Comparing Positron emission tomography and computed tomography results with Histopathological findings served as the standard of reference. True positive, True negative, False positive, False negative. Sensitivity, Specificity, Negative predictive value, Positive predictive value. | Through study completion, an average of 5 year | |
Secondary | Progression free survival | Events of disease recurrence in the study group | Through study completion, an average of 5 year | |
Secondary | Overall survival | Events of death in the study group | Through study completion, an average of 5 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05036681 -
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06192017 -
Development of a Molecular Diagnostic Tool for Endometrial Cancer.
|
||
Completed |
NCT03899441 -
Multimedia Aid Gynecologic Counseling and Consent
|
N/A | |
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Suspended |
NCT03095664 -
Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT01466777 -
Endometrial Cancer and Robotic-assisted Versus Traditional Laparoscopy
|
N/A | |
Completed |
NCT01068483 -
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
|
Phase 1 | |
Recruiting |
NCT03896113 -
Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma
|
Phase 2 | |
Completed |
NCT05246462 -
The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients
|
N/A | |
Withdrawn |
NCT04464967 -
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05651282 -
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
|
Phase 4 | |
Completed |
NCT06187558 -
Suspension of the Pelvic and Abdominal Organs During Minimally Invasive Surgery
|
||
Completed |
NCT06312917 -
Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer
|
N/A | |
Active, not recruiting |
NCT03951415 -
Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT04212910 -
Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
|
||
Completed |
NCT02221076 -
Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.
|
N/A |